← Back to Clinical Trials
Recruiting Phase 2 NCT05879432

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Acute Kidney Injury
Sponsor Arch Biopartners Inc.
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 240
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-08
Completion 2026-08
Interventions
LSALT PeptidePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.

Eligibility Criteria

Inclusion Criteria: 1. Male and female ≥ 18 years of age. 2. Scheduled for a non-emergent coronary and/or valve surgery procedure requiring on-pump cardiopulmonary bypass including but not limited to: * Coronary artery bypass graft (CABG) alone * CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair * Aortic valve replacement or repair alone, with or without aortic root repair * Mitral, tricuspid, or pulmonic valve replacement or repair alone * Simultaneous replacement of several cardiac valves. 3. Have the following AKI risk factors: * CKD Stage 3 (CKD-EPI eGFR ≥ 30 and \< 60 mL/min/1.73 m2) and ONE or more of the following additional risk factors OR * CKD Stage 2 (CKD-EPI eGFR ≥ 60 and \< 90 mL/min/1.73 m2) and ONE or more of the following additional risk factors: * Age ≥ 75 years; * Combined valve \& coronary artery surgery; * Left ventricular ejection fraction (LVEF) ≤ 35% by invasive or noninvasive techniques; * Urinary (TIMP-2 x IGFBP7) \> 0.3 * Diabetes me

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology